What has NICE said?
Tolvaptan (Jinarc) is recommended as a possible treatment for people with autosomal dominant polycystic kidney disease if:
-
they have chronic kidney disease stage 2 or 3 at the start of treatment and
-
there is evidence of rapidly progressing disease.
What does this mean for me?
If you have rapidly progressing autosomal dominant polycystic kidney disease with chronic kidney disease stage 2 or 3 at the start of treatment, and your doctor thinks that tolvaptan is the right treatment, you should be able to have the treatment on the NHS.
Tolvaptan should be available on the NHS within 3 months of the guidance being issued.
If you are not eligible for treatment as described above, you should be able to continue taking tolvaptan until you and your doctor decide it is the right time to stop.